New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Moderna, Inc. (MRNA) Earnings & Analysis

Updated · Covers results through Q3 FY2026 · Earnings call · Latest filing 10-Q filed Nov 6, 2026 · How this is made

Latest quarter

Moderna reported Q3 FY2026 revenue of $1.3 billion, above the $888.8 million consensus. Revenue rose 29.2% from $1.0 billion a year earlier; CFO James Mock said higher COVID vaccine sales were the primary driver.

Moderna reported diluted earnings per share of $0.40, compared with −$0.51 a year earlier. Its gross margin fell to 75.8% from 79.6%, while operating margin moved to 9.90% from −25.6%.

Mock said quarterly cost of sales rose as product sales volume and other manufacturing-related costs increased. He also reported lower research and development expenses, attributing the decline to completed or winding-down infectious disease studies and efficiency gains.

Moderna reported free cash flow of −$1.7 billion for the quarter, compared with −$880.0 million a year earlier. Mock said the company ended the quarter with $8 billion in cash and investments, with financing proceeds partly offset by a litigation settlement payment and seasonal working-capital effects.

Q3 FY2026 Q3 FY2025 Change
Revenue $1.3 billion $1.0 billion 29.2%
Diluted EPS $0.40 −$0.51 —
Gross margin 75.8% 79.6% −3.8 percentage points
Operating margin 9.90% −25.6% 35.5 percentage points
Free cash flow −$1.7 billion −$880.0 million —
Against the consensus Reported Consensus Result
Revenue $1.3 billion $888.8 million Beat by 47.7%

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

Against its own guidance For Guided Reported Result
Revenue Q2 FY2026 $50.0 million–$100.0 million $145.0 million Above the guide

What management said on the call

CFO James Mock said both U.S. and international revenue came in above the company’s expectations, reflecting “increased demand, operational execution, and timing of shipments between the third and fourth quarters.” He said the U.S. vaccination season was still underway, with increased uptake of mNEXSPIKE and vaccination rates relatively stable against the prior year.

Internationally, Mock pointed to execution in the U.K. and Canada and said year-to-date international revenue of $900 million was already $200 million ahead of the full-year 2025 total. Asked about growth beyond this year, he cited flu, Europe and Latin American partnerships among opportunities for 2027, and said Moderna expected to grow next year.

On costs, Mock said quarterly R&D spending fell as infectious disease studies were completed or wound down. He said Moderna expected higher selling, general and administrative expenses in the fourth quarter, primarily because of commercial activity.

CEO Stéphane Bancel said Moderna raised $3 billion through a 0% convertible note and received approximately $2.6 billion in net proceeds after capped calls and fees. Mock said the quarter-end cash balance also reflected a $950 million litigation settlement payment and seasonal working-capital effects.

Bancel said phase 3 results for intismeran, an individualized cancer therapy being developed with Merck, showed a 42% reduction in the risk of recurrence or death in patients with resected melanoma. He also reported U.S. approval of Moderna’s influenza vaccine mFLUSIVA and Canadian approvals for mFLUSIVA and the combined influenza and COVID-19 vaccine mCOMBRIAX.

Asked about the norovirus program, President Stephen Hoge confirmed that the trial had not met its early-success criteria. He said Moderna would consult regulators rather than proceed with another cohort, adding that an update on potential next steps would follow those discussions. On the U.S. flu-COVID combination vaccine, Hoge said Moderna planned to discuss submission expectations with the FDA.

Guidance

Mock raised Moderna’s FY2026 revenue growth outlook to 15% to 25%, from up to 10%, and lowered expected R&D expenses by $200 million to $2.7 billion. He attributed the R&D change to further study wind-downs and operational efficiencies.

Mock said Moderna now expects $4.5 billion in GAAP operating expenses excluding the litigation charge and $3.8 billion in cash costs. He lowered the capital expenditure estimate to $200 million from a range of $200 million to $300 million.

Moderna projected year-end cash and investments of $8.1 billion to $8.3 billion. Mock said that excluding financing proceeds, the projection would be $5.5 billion to $5.7 billion, versus the previous framework of $4.7 billion to $5.2 billion.

Metric For Guide Previous guide Change
Revenue FY2027 Moderna expects to grow in FY2027. — —
Cash, Cash and Investments FY2026 $8.1 billion–$8.3 billion — New
Capex FY2026 $200.0 million $200.0 million–$300.0 million Cut
Operating expenses, Non Gaap Cash Costs FY2026 $3.8 billion — New
Operating expenses, Non Gaap Excluding Litigation FY2026 $4.5 billion — New
Operating expenses, Sga Q4 FY2026 Moderna expects higher SG&A expenses in Q4 FY2026. — —
Operating expenses, Sga FY2026 $1.0 billion $1.0 billion Held
Research and development FY2026 $2.7 billion $2.9 billion Cut
Operating expenses, Cost of Sales FY2026 $1.7 billion $1.7 billion Held
Gross margin FY2026 Moderna expects significant gross margin improvement in FY2026. — —
Revenue, US International Mix FY2026 Moderna expects an approximately even split between U.S. and international revenue in FY2026. — —
Revenue growth FY2026 15.0%–25.0% 10.0% Raised
Cash FY2026 $8.1 billion–$8.3 billion $4.5 billion–$5.0 billion Raised
Operating expenses, Selling General and Administrative FY2026 $1.0 billion — New
Revenue, United States FY2026 Moderna expects approximately half of its FY2026 revenue to come from the United States. — —
Cash, Cash and investments FY2026 $4.7 billion–$5.2 billion — New
Operating expenses, Selling, general and administrative FY2026 $1.0 billion — New
Revenue growth, International revenue mix FY2026 50.0% — New
Revenue growth, U.s. revenue mix FY2026 50.0% — New
Operating expenses, Cash Costs FY2026 $4.0 billion — New
Operating expenses, Excluding Litigation Charge FY2026 $4.7 billion — New
Debt, Undrawn Credit Facility FY2026 $900.0 million — New
Operating expenses FY2026 $4.9 billion — New
Revenue H1 2026 $440.0 million–$490.0 million — New